RecruitingNCT06435585
Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers
Sponsor
Karolinska University Hospital
Enrollment
5,000 participants
Start Date
Feb 17, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
A biobank within the Swedish national heart failure quality registry SwedeHF.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Written informed consent
- Heart failure defined by symptoms and signs of heart failure as judged by the local investigator
- Registered in SwedeHF
Exclusion Criteria3
- Plasma donation within 1 month of enrolment or any blood donation/blood loss \>500 mL during the 3 months prior to enrolment
- Previous allogeneic bone marrow transplant (genetics)
- In the opinion of the investigator, condition/s that may either put the patient at risk on participation or influence the results or the patient's ability to participate in the study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06435585
Related Trials
Mind Your Heart-II
NCT054311921 location
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations